Target Name: GPAT3
NCBI ID: G84803
Review Report on GPAT3 Target / Biomarker Content of Review Report on GPAT3 Target / Biomarker
GPAT3
Other Name(s): AGPAT 10 | 1-acylglycerol-3-phosphate O-acyltransferase 9 | GPAT-3 | GPAT3_HUMAN | 1-acylglycerol-3-phosphate O-acyltransferase 8 | Lysophosphatidic acid acyltransferase theta | 1-acyl-sn-glycerol-3-phosphate O-acyltransferase 10 | hGPAT3 | AGPAT10 | 1-AGPAT 9 | Acyl-CoA:glycerol-3-phosphate acyltransferase 3 | MAG-1 | lung cancer metastasis-associated protein 1 | 1-AGP acyltransferase 9 | MAG1 | glycerol-3-phosphate acyltransferase 3 | Glycerol-3-phosphate acyltransferase 3 | testis secretory sperm-binding protein Li 213e | AGPAT9 | endoplasmic reticulum associated GPAT | GPAT3 variant 1 | 1-acyl-sn-glycerol-3-phosphate O-acyltransferase 9 | LPAAT-theta | Glycerol-3-phosphate acyltransferase 3, transcript variant 1 | Lung cancer metastasis-associated protein 1 | acyl-CoA:glycerol-3-phosphate acyltransferase 3 | lysophosphatidic acid acyltransferase theta | AGPAT8 | HMFN0839

GPAT3: A GPI Molecule with Potential Drug Targets

Glycopharmac molecules (GPI) are a type of glycoprotein on the cell membrane. Their content and distribution have an important impact on cell biology and medicine. GPI is a transmembrane protein composed of 濞???-helix and 閻???-sheet. Its sugar chain interacts with recognition molecules on the cell surface and participates in biological processes such as cell signaling, cell adhesion, cell migration, and cell proliferation. Currently, research on the role of GPI in drug development and disease treatment has attracted increasing attention. This article will introduce the potential role of GPAT3 (AGPAT 10), a GPI, in the field of drug target (or biomarker).

GPAT3 structure and function

GPAT3 is a 12-kDa GPI that, like other GPI family members, consists of two domains: the N-terminal 濞???-helix and the C-terminal 閻???-sheet. The N-terminal 濞???-helix of GPAT3 consists of 35 amino acids, forming a core helical structure, which includes a helical main axis and multiple helical blades. Helical blades are composed of multiple 閻???-helical units that interact through hydrogen bonding of 閻???-strands to form a helical structure.

The C-terminus of GPAT3 is a helical blade region with disulfide bonds, which includes 12 閻???-helical units and is known for its unique secondary domain. In addition, at the C-terminus of GPAT3, there is a transmembrane region, also known as 閻???-curl, which is composed of multiple 閻???-helical units, forming a highly cross-linked 閻???-curl structure.

Biological functions and drug targets of GPAT3

GPAT3 plays an important role in various physiological processes. In the nervous system, GPAT3 is involved in neuronal proliferation, differentiation, and synapse formation. In the immune system, GPAT3 is related to the recognition and activation of immune cells. In tumorigenesis, GPAT3 is associated with tumor cell growth and evasion from immune surveillance.

In recent years, some studies have suggested that GPAT3 may be a potential drug target. For example, GPAT3 has been used as a drug target to treat skin, breast, and ovarian cancers. In addition, GPAT3 is also related to neurological diseases such as Alzheimer's disease and Parkinson's disease.

Research on GPAT3 as a drug target

As a potential drug target, GPAT3 has broad application prospects in the field of drug research and development. Currently, a variety of methods are available to study the function and drug target properties of GPAT3.

1. Proteomics

Proteomics is a method of studying all the proteins in cells. Through high-throughput sequencing technology, it is possible to detect the presence of GPAT3 in cells and understand its expression level. In addition, the interacting proteins of GPAT3 can also be discovered through proteomic studies, providing clues for studying its function.

2. Candidate drug screening

As a drug target, GPAT3 can be used as a target for drug screening. Through high-throughput screening methods, compounds with specific functions can be detected to screen out compounds with potential therapeutic effects.

3. In vivo and in vitro drug efficacy experiments

In in vitro and in vivo efficacy experiments, the efficacy properties of GPAT3 can be tested. For example, by administering the drug orally or by injection, the efficacy of the drug can be observed in animal models or human clinical trials to evaluate the potential and safety of GPAT3 as a drug.

in conclusion

GPAT3 is a transmembrane GPI with potential application value in the field of drug targets (or biomarkers). Through a variety of research methods, the biological functions and drug target properties of GPAT3 can be studied in depth, providing new ideas and targets for the treatment of various diseases.

Protein Name: Glycerol-3-phosphate Acyltransferase 3

Functions: Converts glycerol-3-phosphate to 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) by incorporating an acyl moiety at the sn-1 position of the glycerol backbone (PubMed:17170135). Also converts LPA into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone (PubMed:19318427). Protects cells against lipotoxicity (PubMed:30846318)

The "GPAT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPAT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPAT4 | GPATCH1 | GPATCH11 | GPATCH2 | GPATCH2L | GPATCH3 | GPATCH4 | GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39